An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05369832 |
Recruitment Status :
Recruiting
First Posted : May 11, 2022
Last Update Posted : May 7, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Colitis, Ulcerative | Drug: Ozanimod | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 415 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 4, Prospective, Open-label Study of Ozanimod to Explore the Safety, Efficacy, Quality of Life, and Biomarker Response in Participants With Moderate to Severe Ulcerative Colitis in Clinical Practice |
Actual Study Start Date : | December 16, 2022 |
Estimated Primary Completion Date : | November 29, 2024 |
Estimated Study Completion Date : | April 28, 2027 |
Arm | Intervention/treatment |
---|---|
Experimental: Cohort 1 - Advanced therapy-naive |
Drug: Ozanimod
Specified dose on specified days
Other Names:
|
Experimental: Cohort 2 - Advanced therapy-exposed |
Drug: Ozanimod
Specified dose on specified days
Other Names:
|
- Clinical response as measured by modified Mayo score at Week 12 [ Time Frame: Up to approximately 26 weeks ]Cohort 1 and 2
- Clinical remission as measured by modified Mayo score [ Time Frame: Up to approximately 26 weeks ]Cohort 1 and 2
- Proportion of participants who achieve endoscopic response [ Time Frame: Up to approximately 26 weeks ]Cohort 1 and 2
- Proportion of participants who achieve endoscopic improvement [ Time Frame: Up to approximately 26 weeks ]Cohort 1 and 2
- Proportion of participants who achieve histological improvement [ Time Frame: Up to approximately 26 weeks ]Cohort 1 and 2
- Proportion of participants with change in the Inflammatory Bowel Disease Questionnaire (IBDQ) total score from baseline [ Time Frame: Up to approximately 26 weeks ]Cohort 1 and 2
- Proportion of participants with change in total score (≥ 16 points) of IBDQ response from baseline [ Time Frame: Up to approximately 26 weeks ]Cohort 1 and 2
- Proportion of participants with IBDQ remission with total score of ≥ 170 points [ Time Frame: Up to approximately 26 weeks ]Cohort 1 and 2
- Proportion of participants who achieve endoscopic remission [ Time Frame: Up to approximately 26 weeks ]Cohort 2 only
- Proportion of participants who achieve histological remission [ Time Frame: Up to approximately 26 weeks ]Cohort 2 only
- Corticosteroid-free clinical remission as measured by modified Mayo score [ Time Frame: Up to approximately 26 weeks ]Cohort 2 only
- Proportion of participants with histo-endoscopic mucosal improvement [ Time Frame: Up to approximately 26 weeks ]Cohort 2 only
- Proportion of participants with Adverse Events (AEs) [ Time Frame: Up to approximately 2 years ]Cohort 1 and 2
- Proportion of participants with Serious Adverse Events (SAEs) [ Time Frame: Up to approximately 2 years ]Cohort 1 and 2
- Proportion of participants with AEs of interest (AEI) [ Time Frame: Up to approximately 2 years ]Cohort 1 and 2
- Proportion of participants with AEs leading to discontinuation [ Time Frame: Up to approximately 2 years ]Cohort 1 and 2
- Proportion of participants with clinical laboratory abnormalities [ Time Frame: Up to approximately 2 years ]Cohort 1 and 2
- Clinical remission by partial Mayo score [ Time Frame: Up to approximately 104 weeks ]Cohort 1 and 2
- Corticosteroid-free clinical remission by partial Mayo [ Time Frame: Up to approximately 104 weeks ]Cohort 1 and 2
- Clinical response by partial Mayo score [ Time Frame: Up to approximately 104 weeks ]Cohort 1 and 2
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- A diagnosis of ulcerative colitis (UC), with signs and symptoms consistent with UC for at least 3 months prior to the first study intervention administration
-
Moderate to severely active UC disease activity, defined as a modified Mayo score of 4 through 9, inclusive, with the following minimum subscores:
i) An SF subscore ≥ 1, AND ii) An RB subscore ≥ 1, AND iii) An ES ≥ 2 (endoscopy performed within 60 days of the first study intervention administration).
- Report of a previous colonoscopy that documents extent of disease
Exclusion Criteria:
- Current or recent (within 3 months of screening) evidence of fulminant colitis, toxic megacolon, or bowel perforation
- Extensive colonic resection or current stoma
- Colonic dysplasia that has not been removed
Other protocol-defined inclusion/exclusion criteria apply
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05369832
Contact: BMS Study Connect Contact Center www.BMSStudyConnect.com | 855-907-3286 | Clinical.Trials@bms.com | |
Contact: First line of the email MUST contain the NCT# and Site #. |
Study Director: | Bristol-Myers Squibb | Bristol-Myers Squibb |
Responsible Party: | Bristol-Myers Squibb |
ClinicalTrials.gov Identifier: | NCT05369832 |
Other Study ID Numbers: |
IM047-029 |
First Posted: | May 11, 2022 Key Record Dates |
Last Update Posted: | May 7, 2024 |
Last Verified: | May 2024 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Ulcerative Colitis Ozanimod RPC-1063 Zeposia® Inflammatory bowel disease |
Colitis Colitis, Ulcerative Ulcer Gastroenteritis Gastrointestinal Diseases Digestive System Diseases Colonic Diseases Intestinal Diseases |
Pathologic Processes Inflammatory Bowel Diseases Ozanimod Sphingosine 1 Phosphate Receptor Modulators Molecular Mechanisms of Pharmacological Action Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs |